{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:54:36Z","timestamp":1787964876963,"version":"build-2784847793"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1001\/jamaoncol.2020.6758","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T19:43:47Z","timestamp":1610567027000},"page":"386","source":"Crossref","is-referenced-by-count":152,"title":["Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR<\/i> T790M\u2013Mutated Non\u2013Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor\u2013Tyrosine Kinase Inhibitor"],"prefix":"10.1001","volume":"7","author":[{"given":"Hiroaki","family":"Akamatsu","sequence":"first","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Toi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Furuya","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, St Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Katakami","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Department of Pulmonary Medicine, Chemotherapy Center and Division of Clinical Research, Takarazuka City Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Itami City Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Teraoka","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi200101r1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw279","article-title":"Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival.","volume":"109","author":"Lee","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"coi200101r2","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"75","key":"coi200101r3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6","key":"coi200101r4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/annonc\/mdw129","article-title":"Osimertinib (AZD9291)\u2014a science-driven, collaborative approach to rapid drug design and development.","volume":"27","author":"Yver","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"coi200101r5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"coi200101r6","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","article-title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"coi200101r7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi200101r8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi200101r9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2213-2600(17)30129-7","article-title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.","volume":"5","author":"Rosell","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"20","key":"coi200101r11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.21037\/atm","article-title":"Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer.","volume":"6","author":"Chikaishi","year":"2018","journal-title":"Ann Transl Med"},{"key":"coi200101r12","doi-asserted-by":"publisher","first-page":"ix125","DOI":"10.1093\/annonc\/mdv532.04","article-title":"Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non\u2013small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis.","volume":"26","author":"Hosomi","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"coi200101r13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"coi200101r14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","article-title":"Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial.","volume":"5","author":"Stinchcombe","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"coi200101r15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/JTO.0000000000000434","article-title":"Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.","volume":"10","author":"Ichihara","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"7","key":"coi200101r16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1\/2 single-group open-label trial.","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"coi200101r17","doi-asserted-by":"publisher","first-page":"S453","DOI":"10.1016\/j.jtho.2018.08.545","article-title":"CNS activity of ramucirumab in combination with osimertinib in patients with advanced T790M-positive EGFR-mutant NSCLC.","volume":"13","author":"Paz-Ares","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"2","key":"coi200101r18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"coi200101r19","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/cas.2018.109.issue-6","article-title":"Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.","volume":"109","author":"Akamatsu","year":"2018","journal-title":"Cancer Sci"},{"issue":"9944","key":"coi200101r20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"coi200101r21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy.","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"coi200101r22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway.","volume":"19","author":"Itatani","year":"2018","journal-title":"Int J Mol Sci"},{"key":"coi200101r23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","article-title":"A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.","volume":"99","author":"Yoh","year":"2016","journal-title":"Lung Cancer"},{"issue":"7","key":"coi200101r24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cncr.v122.7","article-title":"Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): an open-label, randomized, phase 2 trial.","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"key":"coi200101r10","unstructured":"World Medical Association. WMA Declaration of Helsinki: ethical principles for medical research involving human subjects. 64th WMA General Assembly, Fortaleza, Brazil. October 2013. Accessed November 30, 2020. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2774521\/jamaoncology_akamatsu_2021_oi_200101_1615397480.54429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:01:53Z","timestamp":1616079713000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2774521"}},"subtitle":["West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.6758","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}